The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Antiemetic efficacy of intravenous (IV) NEPA in patients with breast cancer (BC) receiving anthracycline/cyclophosphamide (AC) chemotherapy.
 
Lee S. Schwartzberg
Stock and Other Ownership Interests - Vector Oncology
Honoraria - Amgen; AstraZeneca; E.R. Squibb Sons, LLC; Genentech; Genomic Health; Helsinn Healthcare; Myriad Genetics; NanoString Technologies; Napo Pharmaceuticals; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Athenex; Biocept; bioTheranostics; Bristol-Myers Squibb; Caris Life Sciences; Coherus Biosciences; E.R. Squibb Sons, LLC; Genentech; Genomic Health; Helsinn Therapeutics; Lilly; Merck; Novartis; Pfizer; Roche; Spectrum Pharmaceuticals; Tesaro
Speakers' Bureau - Coherus Biosciences; Puma Biotechnology
Research Funding - Amgen (Inst); Bayer Health (Inst); E.R. Squibb Sons, LLC (Inst); E.R. Squibb Sons, LLC (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Helsinn Therapeutics; MedImmune (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Tesaro (Inst)
 
Matti S. Aapro
Consulting or Advisory Role - Amgen; Fresenius Kabi; G1 Therapeutics; Genomic Health; Helsinn Healthcare; Merck; Merck KGaA; Novartis; Pfizer; Pierre Fabre; Sandoz; Tesaro; Teva; Vifor Pharma
Speakers' Bureau - Accord Research; Amgen; Biocon; Dr. Reddy's; Genomic Health; Helsinn Healthcare; Mundipharma; Novartis; Pfizer; Pierre Fabre; Roche; Sandoz; Taiho Pharmaceutical; Tesaro; Teva; Vifor Pharma
Research Funding - Helsinn Healthcare (Inst); Hospira; Novartis (Inst); Pierre Fabre (Inst); Sandoz